2026.Sep.10
The Company’s BOD approved to in-license antibody sequences from an U.S. university to strengthen OBI’s next-generation ADC pipeline
Date of occurrence of the event:2026/09/10 Company name:OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios:Not applicable Cause of occurrence:The Company’s Board of Directors approved to in-license monoclonal antibody sequences from an U.S. university to strengthen OBI’s next-generation antibody-drug conjugate (ADC) pipeline. Pursuant to the confidentiality obligations […]
This article is password protected.
To view the content, please enter your password in the field below